Rafael Holdings, Inc. Class B (RFL): Price and Financial Metrics
RFL Price/Volume Stats
| Current price | $1.53 | 52-week high | $2.36 |
| Prev. close | $1.54 | 52-week low | $1.29 |
| Day low | $1.49 | Volume | 5,200 |
| Day high | $1.56 | Avg. volume | 22,761 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $1.64 | Market Cap | 37.59M |
RFL Stock Price Chart Interactive Chart >
Rafael Holdings, Inc. Class B (RFL) Company Bio
Rafael Holdings, Inc., through its subsidiary, manufactures metabolic oncology drugs to treat cancer. The company also owns and operates real estate properties. The company was incorporated in 2017 and is based in Newark, New Jersey. Rafael Holdings, Inc. operates as a subsidiary of IDT Corporation
Latest RFL News From Around the Web
Below are the latest news stories about RAFAEL HOLDINGS INC that investors may wish to consider to help them evaluate RFL as an investment opportunity.
Rafael Holdings GAAP EPS of -$0.15, revenue of $68KMore on Rafael Holdings... |
Rafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsCompany remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investmentsNEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the pot |
Cyclo Therapeutics Reports Third Quarter 2023 Financial ResultsGAINESVILLE, Fla., November 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. |
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsCompany positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunitiesNEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023. “During fiscal 2023, we made meaningful progress toward expanding our portfolio through strategic investments in companies which have th |
Cyclo Therapeutics Reports Second Quarter 2023 Financial ResultsGAINESVILLE, Fla., August 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023. |
RFL Price Returns
| 1-mo | 10.87% |
| 3-mo | 6.99% |
| 6-mo | -11.56% |
| 1-year | -32.60% |
| 3-year | -95.63% |
| 5-year | -92.65% |
| YTD | -16.39% |
| 2023 | -2.14% |
| 2022 | -63.33% |
| 2021 | -78.13% |
| 2020 | 30.72% |
| 2019 | 124.97% |
Continue Researching RFL
Want to see what other sources are saying about Rafael Holdings Inc's financials and stock price? Try the links below:Rafael Holdings Inc (RFL) Stock Price | Nasdaq
Rafael Holdings Inc (RFL) Stock Quote, History and News - Yahoo Finance
Rafael Holdings Inc (RFL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...